REGENXBIO, Inc. (RGNX)
Current
- (-)
After Hours
Rating Performance
Rating Return
-25.42% vs
Rating Accuracy
0.0% (0 of 1*)
Rating Return
-25.42% vs
Rating Accuracy
0.0% (0 of 1*)
Rating Return
-0.43% vs
Rating Accuracy
50.0% (1 of 2*)
Rating Return
+6.04% vs
Rating Accuracy
50.0% (1 of 2*)
FV Performance
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+80.52%
FV Accuracy
1 Hit (7.69% Hit Rate)
FV Avg. Distance
+73.4%
FV Accuracy
1 Hit (4.0% Hit Rate)
FV Avg. Distance
+54.98%
FV Accuracy
14 Hits (28.57% Hit Rate)
FV Avg. Distance
+40.49%
*There is a current rating on the stock that is included in these numbers based on its performance so far
About
CEO
Kenneth T. Mills
Employees
257
Industry
Neurology Biopharmaceuticals
Sector
Healthcare
Headquarters
Rockville
Exchange
NASDAQ
Website
http://www.regenxbio.comSummary Stats
Market Cap
870M
Revenue
474M
Net Income
101M
EPS
$2.29
Price-to-Earnings
8.81
Price-to-Book
1.26
Debt-to-Equity
0.49
News
Analyst Ratings
Price targets projected by 8 analysts
High
$100.00
Average
$57.50
Low
$31.00
Ratings calculated by 8 analysts
Buy
6
Hold
2
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q1 2022
Missed by -$0.26
-$1.58 -19.7%
-1.32
-1.2
Down 31%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--